Abstrato

Hypoxanthine of Ischemic Brain Edema Modified by Glibenclamide

Sun Jing

The development of malignant brain edema is a leading cause of early clinical deterioration and death after ischemic stroke. Lesional swelling exacerbates tissue injury and portends poor long-term functional outcome after stroke. Malignant brain edema [1], the rapid clinical decline in the first 24–72 h after stroke due to mass-occupying tissue swelling, is a highly morbid sequela of large hemispheric stroke. Limited therapies exist for the treatment of brain edema.